1 domain / 2 areas / 1 specialization
Tabula Rasa Ventures
Data updated
Tabula Rasa Ventures is a venture capital firm focused on investing in health-related companies, including drug development, healthcare infrastructure, and digital therapeutics. Its website and profiles describe it as an early-stage investor with activity from pre-seed and seed through growth-stage financing. Public-facing sources point to New York, New York, in the United States as its base of operations.
It matters in the psychedelic ecosystem because Tabula Rasa has explicitly backed psychedelic companies and frames part of its work around psychedelic and psychedelic-adjacent entrepreneurship. Its portfolio page includes Lykos Therapeutics and Natural MedTech, both tied to psychedelic drug development and research, and the firm has also described itself as supporting a psychedelic business incubator.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Public Portfolio Examples
- Lykos TherapeuticsSeries A - $100M - Sep 29, 2023
- Natural MedTechJan 1, 2021
Tabula Rasa Ventures presents itself as a health-focused venture investor with a strong emphasis on evidence-based development, early company building, and stakeholder alignment. In the psychedelic space, it is relevant because it has publicly associated itself with psychedelic and psychedelic-adjacent investing, including companies working on investigational psychedelics and formal psychedelic research. Its public materials suggest a strategy that starts early and can continue into later financing as companies scale within drug development and broader health infrastructure.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Recorded Investments
Sep 29, 2023
Series A - $100M
Public funding summary lists Tabula Rasa Ventures among investors in Lykos Therapeutics, a psychedelic drug development company.
Lykos Therapeutics Stock Price, Funding, Valuation, Revenue & Financial StatementsNatural MedTech
Jan 1, 2021
Portfolio entry ties Tabula Rasa to a company conducting formal psychedelic research in Australia.
Natural Medtech - Tabula Rasa VenturesQuick Facts
- HQ
- New York, New York, United States
- Website
- Visit